AMT-130 gene therapy: a promising disease-modifying approach for Huntington’s disease

Huntington's disease (HD) is a progressive, autosomal dominant neurodegenerative disorder caused by expanded Cytosine-Adenine-GuanineCAG repeats in the huntingtin (HTT) gene, leading to the production and accumulation of mutant huntingtin protein and subsequent neuronal dysfunction and loss. Current management remains largely symptomatic, with no established disease-modifying therapy. AMT-130 represents a novel and promising approach aimed at directly targeting the underlying molecular pathology of HD. AMT-130 is a one-time gene therapy that utilizes an adeno-associated virus serotype 5 (AAV5) vector to deliver an engineered microRNA (miHTT) into the caudate and putamen via stereotactic intracerebral infusion. This microRNA selectively reduces HTT mRNA levels, resulting in sustained lowering of mutant huntingtin protein. Preclinical studies in both large-animal and rodent models have demonstrated broad vector distribution, long-term expression, significant reduction in huntingtin levels, improved motor performance, decreased neuronal degeneration, and prolonged survival. Early Phase I/II clinical data indicate a favorable safety profile, reductions in neurofilament light chain levels, and stabilization of motor and functional decline, particularly in high-dose cohorts, suggesting a potential slowing of disease progression. While long-term efficacy and broader clinical validation are still required, AMT-130 shows strong potential to shift HD treatment from purely symptomatic care toward meaningful disease modification. Its success may also pave the way for microRNA-based therapies in other neurodegenerative disorders.